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Background
Peritoneal carcinomatosis is a frequent evolution of gas-
trointestinal and gynecologic malignancy and it has been
regarded as a lethal clinical entity. Treatment options
for these patients have improved significantly in the past
few years. CytoReductive Surgery (CRS) plus Hyperther-
mic IntraPEritoneal Chemotherapy (HIPEC) is an
aggressive and promising treatment for patients with
peritoneal malignancies. Whether this type of major
cancer surgery is feasible in elderly patients is an
ongoing question.
Materials and methods
For this study we have only considered the patients with
a minimal follow up of 18 months. For this reason we
have evaluated 30 patients, 11 (36,6%) aged > 65 years,
submitted, in the period May 2004 –April 2008, to 33
CRS plus HIPEC. Criteria of patients’ eligibility were
peritoneal carcinomatosis of different origins, T3-4
gastric cancer, ECOG performance status ≤2, no extra-
abdominal extension and no evidence of bowel obstruc-
tion. For the intraoperative staging we have used the
“Peritoneal Cancer Index” ( P C I )[ 1 ]a n dt oe v a l u a t et h e
entity of cytoreduction the “Completeness of Cytoreduc-
tion score” (CC score) [2] (Figure 1).
Results
Results of our experience are reported in Table 1.
Conclusions
The rationale of CRS plus HIPEC is based respectively
on the removal of gross disease and on the eradication
of microscopic residual disease. The peritoneal-plasma
barrier retards the clearance of high molecular weight
chemotherapy from the peritoneal cavity and allows a
large exposure of small residual cancer nodules. Tissue
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Figure 1 Peritoneal Cancer Index and Completeness of Cytoreduction score
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© 2010 Macrì et al; licensee BioMed Central Ltd.penetration of the intraperitoneal chemotherapy is facili-
tated by moderate hyperthermia (41-42ºC). This promis-
ing therapeutic approach is associated with significant
morbidity and mortality and the surgical risk in elderly
patients is even higher, since these people suffer from
frequent comorbidities [3]. In our experience we have
recorded, in elderly patients, higher, but acceptable,
morbidity (27,2% vs 18,1%) and mortality (18,1% vs
4,5%), probably correlated with their comorbidities
(100% vs 36,8%), lower mean postoperative hospital stay
(15,6 days vs 17,2) and a good 18-months overall survi-
val (63,6%). We retain, on the basis of our experience
and of the data of the literature [3], that age and
advanced peritoneal malignancy should not preclude
patients from the maximal surgical effort.
Author details
1University of Messina, General Surgery Unit, Messina, Italy.
2University of
Messina, Medical Oncology Unit,Messina, Italy.
3Ospedali Riuniti della Locride,
Hospital of Siderno, Medical Oncology Unit, Siderno, Italy.
4University of
Messina, Anesthesiology Unit, Messina, Italy.
5University of Messina,
Gynecologic Oncology Unit, Messina, Italy.
Published: 19 May 2010
References
1. Quantitative methodologies for selection of patients with recurrent
abdominopelvic sarcoma for treatment.. Berthet B, Sugarbaker TA, Chang D,
Sugarbaker PH: Eur J Cancer 1999, 35(3):413-9.
2. Sugarbaker PH: Current Indications for Cytoreductive Surgery and
Intraperitoneal Chemotherapy. Management of peritoneal surface
malignancy using intraperitoneal chemotherapy and cytoreductive surgery. The
Ludann Company Grand Rapids eds., Michigan. 1998, 18.
3. Mueller H, Hahn M, Simsa J: Cytoreductive surgery in the elderly
patients–is it feasible? Hepatogastroenterology 2008, 55(88):2005-11.
doi:10.1186/1471-2318-10-S1-A11
Cite this article as: Macrì et al.: The treatment of peritoneal
carcinomatosis in elderly patients. BMC Geriatrics 2010 10(Suppl 1):A11.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Table 1 characteristics of patients and results
Pts Procedures Mean
age
(range)
Chronic
comorbidities
Mean duration
of surgery
(min.)
Mean
PCI
CC score Mean postop.
hospital stay
(days)
Morbidity Mortality 18 mths
overall
surv.
Total 30 33 58,3
(30-77)
18/30 (60%) 556,7 8,2 29 pts: 0
3pts:1
1 pt.
with
relapse: 2
17 21,2% 9% 66,6%
Pts aged
<6 5
years
19 22 52,7
(30-63)
7/19 (36,8%) 551,3 8,1 19 pts: 0
2 pts: 1
1 pt.
with
relapse: 2
17,2 18,1% 4,5% 68,4%
Pts aged
>6 5
years
11 11 69,7
(66-77)
11/11 (100%) 567,5 8,2 10 pts: 0
1 pt: 1
15,6 27,2% 18,1% 63,6%
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